Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis
NCT ID: NCT04561687
Last Updated: 2020-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
66 participants
INTERVENTIONAL
2020-01-16
2021-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inflammation of the nasal mucosa following the release of IgE can be shown as symptoms of runny nose, sneezing, nasal congestion.Many studies have been done in the field of allergic rhinitis to increase the cost-effectiveness of treatment of this complication. Among the treatments for this disease is the use of antihistamine nasal sprays such as Azelastine. Combination therapies such as combining Mometason furoate or fluticasone with Azelastine or Montelukast can also be mentioned. However, there is still a long way to go to find the best drug combination to reduce the economic and human costs to the global health system. Due to the high prevalence of allergic diseases such as allergic rhinitis, finding the best treatment or management of such diseases plays an important role in improving the quality of life and reducing the economic burden on society.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
NCT05080322
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00883168
Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
NCT01470053
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660517
Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients
NCT04729517
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Azelastine and Nasal Budesonide
Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older
Azelastine
Azelastine and nasal budesonide
Budesonide
To all groups
Montelukast and Nasal budesonide
Montelukast 5mg 6-14years old and 10mg for older
Montelukast
Montelukast and nasal budesonide
Budesonide
To all groups
Nasal Budesonide and Placebo
Placebo once daily
Budesonide
To all groups
Placebo
Placebo and nasal budesonide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Montelukast
Montelukast and nasal budesonide
Azelastine
Azelastine and nasal budesonide
Budesonide
To all groups
Placebo
Placebo and nasal budesonide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Moderate to severe allergic rhinitis
Exclusion Criteria
* Drug sensitivity
6 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shiraz University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nasrin Mortazavi Far
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nasrin Mortazavi
Role: PRINCIPAL_INVESTIGATOR
Shiraz University of Medical Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shiraz University of Medical Science
Shiraz, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
98-01-49-21547
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.